Studies reveal that the air inside our homes is more polluted than the air outdoors, and a portion of these toxins come from ...

Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...

Axsome Therapeutics reports 66% Q4 revenue growth, blockbuster potential for Auvelity, and robust pipeline progress with 3 NDA filings and key ...

potentially impacting its commercial success. A single dose of SYMBRAVO can provide migraine pain freedom within 2 hours. What percentage of patients do not need rescue medication after SYMBRAVO?

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Operator Good morning, and welcome to the Axsome Therapeutics fourth quarter and full year 2024 conference call. Currently, all participants are in listen-only mode. Later, there will be a ...

It targets multiple pathways underlying a migraine attack ... The latest FDA nod for Symbravo diversifies Axsome’s commercial drug portfolio. The company currently markets Auvelity (AXS-05 ...

Gemma Jolly of medical charity the Migraine Trust said NICE’s recommendation ... have performed well in clinical trials, but so far commercial success has been limited, despite blockbuster ...

Reports Q4 revenue $118.8M, consensus $117.84M. “2024 was another defining year for Axsome, driven by strong commercial growth and a rapidly ...

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by equities research analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research report issued ...

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.